Last reviewed · How we verify
MB07133
At a glance
| Generic name | MB07133 |
|---|---|
| Sponsor | Xi'an Xintong Pharmaceutical Research Co.,Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma (PHASE1, PHASE2)
- MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma (PHASE2)
- Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB07133 CI brief — competitive landscape report
- MB07133 updates RSS · CI watch RSS
- Xi'an Xintong Pharmaceutical Research Co.,Ltd. portfolio CI